newsfilter
← Latest News
GlobeNewswire·

Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M

Company Initiates Regulatory Discussions with CDSCO; Plans 408-Patient Pivotal Study Targeting Standard-Risk Several Viral Infected Outpatients BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB:BIXT)